Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

Add To Watchlist

GREY:ATBPF - Post Discussion

Antibe Therapeutics Inc(Pre-Merger) > $1.50 Avg price target

View:

Post by Duster340 on Nov 25, 2022 9:37am

$1.50 Avg price target

In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Antibe Therapeutics (ATBPF – Research Report), with a price target of C$2.00. The company’s shares opened today at $0.35.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Antibe Therapeutics with a $1.50 average price target, implying a 328.57% upside from current levels. In a report released on November 15, Echelon Wealth Partners also maintained a Buy rating on the stock with a C$2.00 price target.

453